NGL Fine Chem Ltd Valuation Shifts Amidst Robust Price Gains

Price Performance Outpaces Sensex

The stock price of NGL Fine Chem Ltd closed at ₹3,063.60 on 15 Jun 2026, marking a substantial 12.85% gain on the day and reaching a 52-week high of ₹3,122.25. This rally has been part of a broader upward trajectory, with the stock delivering a remarkable 117.43% return year-to-date (YTD), starkly contrasting with the Sensex’s negative 11.37% return over the same period. Over the past year, NGL Fine Chem has surged 187.41%, while the Sensex declined by 7.55%. Even over a decade, the stock has outperformed the benchmark by a wide margin, returning 1,188.58% compared to the Sensex’s 183.56%.

Valuation Metrics Signal Elevated Price Levels

Despite the strong price momentum, valuation parameters have shifted markedly, raising concerns about the stock’s price attractiveness. The P/E ratio currently stands at 40.12, a level that categorises the stock as very expensive within its sector. This is a notable increase compared to many peers, such as Bliss GVS Pharma (P/E 35.64) and Kwality Pharma (P/E 37.8), both also rated very expensive but still below NGL Fine Chem’s multiple.

The price-to-book value ratio has climbed to 5.85, further underscoring the premium investors are paying relative to the company’s net asset base. This elevated P/BV ratio is significantly higher than the industry average and signals stretched valuations, especially for a micro-cap pharmaceutical firm.

Enterprise Value Multiples and Profitability Ratios

Enterprise value to EBITDA (EV/EBITDA) ratio is at 27.72, again placing NGL Fine Chem among the most expensive in its peer group. Comparatively, peers like Bliss GVS Pharma and Hester Bios have EV/EBITDA ratios of 27.49 and 21.24 respectively, indicating that NGL Fine Chem’s valuation premium is not isolated but still at the upper end.

Return on capital employed (ROCE) and return on equity (ROE) stand at 13.29% and 14.59% respectively, reflecting decent profitability but not sufficiently high to justify the stretched valuation multiples. The PEG ratio, which adjusts the P/E for earnings growth, is low at 0.31, suggesting that the market is pricing in strong future growth expectations. However, this figure should be interpreted cautiously given the already elevated absolute valuation levels.

Comparative Valuation Context

Within the Pharmaceuticals & Biotechnology sector, NGL Fine Chem’s valuation grade has shifted from expensive to very expensive, a move that has contributed to the downgrade in its mojo grade from Buy to Hold as of 11 Jun 2026. This reclassification reflects a more cautious stance given the stretched multiples and the risk of valuation correction.

Other companies in the sector such as Venus Remedies and Lincoln Pharma present more attractive valuation profiles, with P/E ratios of 23.42 and 14.47 respectively, and EV/EBITDA multiples well below NGL Fine Chem’s. Lincoln Pharma, in particular, is rated as attractive, highlighting the relative premium investors are paying for NGL Fine Chem’s growth narrative.

Implications for Investors

The sharp rise in valuation multiples, particularly the P/E and P/BV ratios, suggests that the market has priced in significant growth expectations for NGL Fine Chem. While the company’s operational metrics such as ROCE and ROE are respectable, they do not fully justify the very expensive valuation grade. Investors should weigh the risk of a potential valuation correction against the company’s strong price momentum and sectoral tailwinds.

Given the micro-cap status of NGL Fine Chem, liquidity and volatility considerations also come into play. The stock’s recent 12.85% single-day gain and 39.45% return over the past month indicate heightened investor interest but also increased price sensitivity to market news and sentiment shifts.

Sector and Peer Comparison

Within the Pharmaceuticals & Biotechnology sector, valuation dispersion is wide. While some peers trade at more moderate multiples, others like Shukra Pharma exhibit even higher P/E ratios (49.74) and EV/EBITDA multiples (45.41), indicating pockets of extreme valuation within the sector. This context is important for investors seeking relative value opportunities.

Furthermore, the dividend yield of NGL Fine Chem is negligible at 0.06%, which may deter income-focused investors. The company’s PEG ratio of 0.31, while low, must be balanced against the absolute high P/E, suggesting that earnings growth expectations are baked into the price but with limited margin for error.

Outlook and Strategic Considerations

Investors should consider the recent mojo grade downgrade from Buy to Hold as a signal to reassess their exposure to NGL Fine Chem. The company’s micro-cap status and very expensive valuation multiples suggest that while growth prospects remain promising, the risk-reward balance has shifted.

For those seeking exposure to the Pharmaceuticals & Biotechnology sector, it may be prudent to explore alternatives with more attractive valuation profiles or stronger dividend yields. Monitoring quarterly earnings and sector developments will be crucial to gauge whether NGL Fine Chem can sustain its elevated valuation levels.

In summary, NGL Fine Chem Ltd’s valuation parameters have moved decisively into very expensive territory, reflecting strong investor enthusiasm but also heightened risk. The stock’s exceptional price performance relative to the Sensex underscores its growth credentials, yet the premium multiples warrant a cautious approach.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →